RxDoctor Payments Data

John Watson, MD

Internal Medicine · Reno, NVNPI 1366460347

Payments from drug & device makers

$763in general payments, 2019–2025

Across 37 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$412
  • Pfizer$96
  • Astellas Pharma US Inc$78
  • GSK$57
  • AstraZeneca$38
  • E.r. Squibb & Sons, L.L.C.$23
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$763 in reported general payments places this provider in the 65th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$213,309
Medicare patients
561
Services billed
2,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide215$319,788
JardianceEmpagliflozin158$257,971
EliquisApixaban127$161,200
TrulicityDulaglutide94$156,721
FarxigaDapagliflozin Propanediol85$112,249
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$99,339
JanuviaSitagliptin Phosphate58$72,449
XareltoRivaroxaban48$72,124
MounjaroTirzepatide30$44,578
MyrbetriqMirabegron23$25,646
RexultiBrexpiprazole15$24,188
Breo ElliptaFluticasone/Vilanterol25$20,494
TradjentaLinagliptin21$19,984
Atorvastatin Calcium1,211$17,547
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$15,891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$22$319,788215 claims
PfizerEliquis$96$161,200127 claims
GSKTrelegy Ellipta, Breo Ellipta$57$119,83395 claims
AstraZenecaFarxiga, Symbicort$38$117,94296 claims
Astellas Pharma US IncMyrbetriq$78$25,64623 claims
AbbVieSynthroid$412$2,41448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →